Loading patent…
AssigneeBiogen, Inc.
InventorsJeffrey L. Browning, Christopher D. Benjamin, Paula S. Hochman
Estimating the term…
This invention relates to compositions and methods comprising “lymphotoxin-β receptor blocking agents”, which block lymphotoxin-β receptor signalling. Lymphotoxin-β receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-β receptor extracellular domain that act as lymphotoxin-β receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-β receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-β receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-β receptor signalling is provided.
A method for treating or reducing the advancement, severity or effects of a Th1 cell-associated autoimmune disease in an animal comprising the step of administering a pharmaceutical composition which comprises a therapeutically effective amount of a soluble lymphotoxin-β receptor (LT-β-R) fused to one or more heterologous protein domains and a pharmaceutically acceptable carrier.
A pharmaceutical composition comprising a therapeutically effective amount of a soluble lymphotoxin-β receptor (LT-β-R) fused to one or more heterologous protein domains and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.